Adjunctive Statin Therapy in Patients with Covid-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials - 25/09/24
, Beatriz Araújo b, Vitor Leão Durães a, Ivo Queiroz c, Vanessa Henriques Carvalho, MD, PhD d, Tahir Haque, MD e, Taniela M. Bes, MD, PhD f
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
The efficacy and safety of adjunctive statin therapy in hospitalized patients with coronavirus disease 2019 (Covid-19) remains uncertain.
Methods |
We systematically searched Medline, Embase, Cochrane, and ClinicalTrials.gov databases from inception to late April 2024 for randomized controlled trials (RCTs) comparing statin versus no statin use in patients hospitalized with Covid-19. We pooled risk ratios (RRs) and hazard ratios (HRs) with 95% confidence intervals (CIs) applying a random-effects model. R version 4.3.1 was used for statistical analyses.
Results |
We included 7 RCTs comprising 4,262 patients, of whom 2,645 (62%) were randomized to receive statin therapy. Compared with no statin, statin use significantly reduced case-fatality rate (RR 0.88; 95% CI 0.80-0.98; I2 = 0%). In a time-to-event analysis, we found similar results (HR 0.86; 95% CI 0.75-0.99; I2 = 0%). Statin use also significantly reduced World Health Organization (WHO) scale at 14 days (mean difference -0.27; 95% CI -0.54 to -0.01; I2 = 0%). There was no statistically significant difference between the two groups in length of hospital stay, elevation of liver enzymes, and C-reactive protein levels.
Conclusions |
In patients hospitalized with Covid-19, statins significantly reduced case-fatality rate and WHO scale score.
Registration |
A prospective register was recorded in International Prospective Register of Systematic Reviews (PROSPERO) with the number CRD42023479007.
Le texte complet de cet article est disponible en PDF.Keywords : Case-fatality rate, Coronavirus, Covid-19, Statins
Plan
| Funding: There were no external funding sources for this study. |
|
| Conflict of Interest: All authors declare no conflicts of interest and take full responsibility for the data's reliability and unbiased interpretation. |
|
| Cynthia Florêncio de Mesquita, André Rivera, Beatriz Araújo, Vitor Leão Durães, and Ivo Queiroz Costa Neto are medical students. |
|
| Authorship: CFM: Writing – original draft, Project administration, Methodology, Data curation, Conceptualization. AR: Writing – original draft, Visualization, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. BA: Writing – original draft, Investigation, Formal analysis, Data curation. VD: Writing – original draft, Investigation, Data curation. IQ: Writing – review & editing, Methodology, Investigation, Formal analysis. VHC: Data curation. TH: Writing – review & editing. TMB: Writing – review & editing, Project administration. |
Vol 137 - N° 10
P. 966 - octobre 2024 Retour au numéro
Article précédent
- Antithrombotic Strategies According to Age: Insights from the AUGUSTUS Trial
- Patricia O. Guimarães, Renato D. Lopes, Daniel M. Wojdyla, John H. Alexander, Shaun G. Goodman, Ronald Aronson, Sigrun Halvorsen, Peter Sinnaeve, Dragos Vinereanu, Robert F. Storey, Otavio Berwanger, Stephan Windecker, Roxana Mehran, Christopher B. Granger, Karen P. Alexander, AUGUSTUS Investigators
- Prior Nonmelanoma Skin Cancer is Associated with Fewer Fractures, More Vitamin D Sufficiency, Greater Bone Mineral Density, and Improved Bone Microarchitecture in Older Adults
- Michael Thompson, Graeme Jones, Alison Venn, Saliu Balogun, Flavia Cicuttini, Bruna Ragaini, Dawn Aitken
Bienvenue sur EM-consulte, la référence des professionnels de santé.